Description
The use of AI for allergic disorders originated at the turn of this century. Until 1986, AI was widely used in the UK, and general consensus reached regarding its efficacy for the treatment of seasonal allergic rhinitis and hymenoptera-induced anaphylaxis. Its use for asthma and perennial allergic rhinitis remains contentious. AI has not been found useful for the treatment of atopic dermatitis, urticaria and food intolerance.
In 1986, the Committee on Safety of Medicines issued a report1 on fatalities and adverse reactions associated with AI, which appeared to be increasing particularly in asthmatic patients. This led to the imposition of stringent restrictions on the practice of AI, effectively curtailing its administration in general practice. In the absence of a system of hospital-based allergy clinics, the practice of AI in the UK became restricted to a small group of interested hospital specialists.
